The “Hopp Children’s Cancer Center Heidelberg” (KiTZ) is a joint initiative of the German Cancer Research Center (DKFZ), Heidelberg University Hospital and Heidelberg University.
Brain tumors that look similar under the microscope can differ strongly on a molecular level - a distinction that should be considered when making treatment decisions. Children with embryonal brain tumors have to undergo intense and devastating therapies, with an overall limited curative outcome for some tumor subtypes. This holds true for “supratentorial primitive neuroectodermal tumors (sPNETs)”: These tumors derive from immature cells of the central nervous system (CNS), growing particularly fast and aggressively.
The team surrounding Professor Stefan Pfister, KiTZ director, head of the “Pediatric Neurooncology” division of the DKFZ and senior physician at the Heidelberg University Hospital, conducted the study together with colleagues of the Fred Hutchinson Cancer Research Center (Seattle, USA) and the Children’s National Medical Center (Washington DC, USA). Using a state-of-the-art data analysis method, the researchers analyzed chemical gene modifications, so-called DNA methylation, within the patients` tumor tissue in the context of a phase-III clinical trial on sPNETs.
Molecular diagnostic tumor classification prior to treatment could prevent devastating therapies for many children. “An exact diagnosis and prognosis assessment for most children with CNS tumors is possible when histological examinations are combined with methylation analyses of the tumor DNA”, says Professor Pfister, a main author of the study. “We can thus better estimate who would benefit from the intense radiation and chemotherapy and which treatment option should be used. This way we are able to save children from the side-effects of non-beneficial therapies.”
In the context of this study the methylation analysis showed that fewer patients than assumed truly suffered from sPNET, but the majority had other tumor types such as glioblastoma, ependymoma or others that had been misdiagnosed. Accounting for these “false positives”, the prognosis for sPNET is much better than previously assumed, with an increased chance of responding well to chemotherapy.
Since the molecular characterization of embryonal tumors of the central nervous system in children can therefore have a crucial impact on treatment types and therapy success, the researchers recommend to implement this method as a standard-of-care method for diagnosis.
Hwang et al. 2018: Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children’s Oncology Group Randomized ACNS0332 Trial. DOI: 10.1200/JCO.2017.76.4720. Journal of Clinical Oncology – Online publication on October 17, 2018.
Dr. Elke Matuschek
Hopp Children’s Cancer Center Heidelberg (KiTZ)
Press and Public Relations Officer
Im Neuenheimer Feld 130.3 / 7.320
T: +49 (0) 6221 56 36434